| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | DVAX | Common Stock | Options Exercise | $9,423 | +900 | +11% | $10.47 | 9,176 | 01 Sep 2021 | Direct | F1 |
| transaction | DVAX | Common Stock | Sale | $18,135 | -900 | -9.8% | $20.15 | 8,276 | 01 Sep 2021 | Direct | F1, F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | DVAX | Stock Option (Right to Buy) | Options Exercise | -900 | -0.87% | 103,100 | 01 Sep 2021 | Common Stock | 900 | $10.47 | Direct | F1, F3, F4 |
| Id | Content |
|---|---|
| F1 | The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on August 11, 2020. |
| F2 | This transaction was executed in multiple trades at prices ranging from $20.03 to $20.25; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax. |
| F3 | This option grant will vest over three (3) years with one-third (1/3) of the shares subject to the option vesting twelve months after the grant date, and one thirty-sixth (1/36) of the shares subject to the option vesting on the last day of each month thereafter. |
| F4 | Not applicable. |